Skip to content

Depression: all studies

Page 102 of 1,034: studies 1,011 to 1,020 of 10,336, newest first. Back to the depression overview

Research

Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.

GeroScience March 25, 2025 Anna Łysik, Katarzyna Logoń, Aleksandra Szczygieł et al. 8 citations

Treatment-resistant depression (TRD) remains a vital challenge in psychiatry, affecting a significant number of patients with major depressive disorder. Current pharmacological approaches often do not provide sufficient therapeutic results, prompting the need for innovative treatments. This review summarizes recent advances in TRD management, including non-pharmacological therapies such as...

Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression.

Journal of Psychopharmacology March 24, 2025 Chung-Feng Kao, Shih-Jen Tsai, Tung-Ping Su et al. 1 citation

Low-dose ketamine is an N-methyl-D-aspartate receptor antagonist that exerts an antidepressant effect on patients with treatment-resistant depression (TRD). This antidepressant effect may extend beyond the glutamatergic hypothesis. Nevertheless, the roles of genes encoding other monoamine neurotransmitters (i.e., serotonin and dopamine) in the neuromechanism of low-dose ketamine remain unknown....

DOI: 10.1177/02698811251326939 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Neurotransmitter studies Psychiatric genomics Antidepressant mechanisms +4

A Critical Advantage of Hypnobirthing to Ameliorate Antenatal Depression: A Systematic Review and Meta-Analysis.

Healthcare March 23, 2025 Feni Betriana, Sunarno Sunarno, Wiwit Nurwidyaningtyas et al.

Pregnant women are likely to experience depression due to various factors. Hypnobirthing is a non-invasive therapy that can be used to treat depression during pregnancy. This study aims to systematically review the effect of hypnobirthing on antenatal depression. This study employs a systematic review following PRISMA guidelines. Articles were retrieved from PubMed, ScienceDirect, the Cochrane...

Oral Ketamine for the Treatment of Depression: A randomized controlled trial and meta-analysis

medRxiv Preprint Server March 21, 2025 Leo R. Silberbauer, Benjamin Eggerstorfer, Paul Michenthaler et al. 1 citation preprint

Background Ketamine represents a significant advancement in antidepressant therapy, but the commonly used intravenous and intranasal application routes currently limit its availability beyond specialized centers. By contrast, oral ketamine treatment might constitute an alternative that is easy to administer with established safety and efficacy for patients with chronic and severe pain at home.

DOI: 10.1101/2025.03.21.25324252 (opens in new tab) Full text (opens in new tab) Depression treatment Mental health management Mood disorder therapy Antidepressant care +18

Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review.

Medicina (Kaunas, Lithuania) March 21, 2025 Keming Gao, Evrim Bayrak Oruc, Buket Koparal 9 citations

Objective: To narratively review currently available antidepressants and future potential antidepressants as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake inhibitor (bupropion), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) were...

DOI: 10.3390/medicina61040558 (opens in new tab) Full text (opens in new tab) N-methyl-d-aspartate receptor antagonists Anti-inflammatory agents Biomarker antidepressant therapy Depressive disorders +9

A Pre-Experimental Study to Assess the Impact of Mindfulness Meditation on Stress, Anxiety and Depression among the Senior Secondary Students Studying In Government School, Chandigarh

i-manager's Journal on Nursing March 20, 2025 Manpreet Kaur, Parul Sharma, Prince Harkaul et al.

A Pre-experimental study was conducted to assess the impact of Mindfulness Meditation on Stress, Anxiety and Depression among the Senior secondary Students Studying in Government School, Chandigarh. The objectives of the study are to identify the factors affecting stress, anxiety and depression among senior secondary students and to assess the impact of mindfulness meditation by comparing...

A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress

Cureus March 17, 2025 Fejzic Dino 1 citation

The purpose of this review is to provide a comprehensive overview of the current findings and data on the therapeutic effects of psilocybin, a naturally occurring psychedelic alkaloid primarily found in Psilocybe mushrooms. This review covers psilocybin's efficacy and safety profile, therapeutic effects, proposed indications and contraindications, drug-drug interactions, adverse reactions,...

Associations between hypothalamic-pituitary-adrenal (HPA) axis hormone levels, major depression features and antidepressant effects of ketamine.

Journal of Affective Disorders March 15, 2025 Polymnia Georgiou, Cristan A Farmer, Gustavo C Medeiros et al. 24 citations

Subanesthetic doses of (R,S)-ketamine (ketamine) have demonstrated rapid and robust antidepressant effects in individuals with depression. However, individual variability in response to ketamine exists, and current biomarkers of ketamine treatment response are not entirely understood. Preclinical evidence suggests a link between hypothalamic-pituitary-adrenal (HPA) axis activation, a...

DOI: 10.1016/j.jad.2024.12.036 (opens in new tab) Full text (opens in new tab) Depression Adrenocorticotropic hormone Corticotropin releasing factor Cortisol +4

Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.

Journal of Affective Disorders March 15, 2025 Kevin H. Yang, Wayne Kepner, Charles M Cleland et al. 19 citations

Ketamine's potential for treating depression has drawn increased clinical interest in recent years. However, despite growing therapeutic use, recreational use among individuals with depression remain underexplored. We analyzed data from the 2015-2022 National Survey on Drug Use and Health focusing on adults in the US. Trends in past-year ketamine use, overall and by depression status, were...

DOI: 10.1016/j.jad.2024.12.108 (opens in new tab) Full text (opens in new tab) Depression Nationally representative samples Ketamine-use-trends Mental-health-epidemiology +2

Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression

bioRxiv (Cold Spring Harbor Laboratory) March 10, 2025 Shaun K.l. Quah, Cameron C. Glick, Leor Roseman et al. preprint

Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain networks. Yet, it is unclear whether similar alterations are observed when nonlinear FC is examined. This study investigated how antidepressant treatment (i.e., psilocybin and escitalopram) modulates both linear FC and nonlinear FC in individuals with MDD....

DOI: 10.1101/2025.03.05.641592 (opens in new tab) Full text (opens in new tab) Psilocybin Escitalopram Functional connectivity Depression economics +4